WO2025067622A1 - Cannabidiol for use in alleviating xerostomia - Google Patents

Abstract

The invention relates to use of cannabidiol in the alleviation or treatment of xerostomia in patients in need thereof. Particularly, the invention pertains to cannabidiol (CBD) for use in the alleviation or treatment of xerostomia according to claim 1, wherein the cannabidiol is administered orally, such as by peroral administration or by sublingual administration.

Description

CANNABIDIOL FOR ALLEVIATING XEROSTOMIA FIELD OF THE INVENTION The invention relates to the field of cannabinoids. In particular, the invention relates to cannabidiol (CBD) for use in the alleviation or treatment of xerostomia in patients in need thereof as well as methods treating or alleviating xerostomia in patients in need thereof. BACKGROUND OF THE INVENTION One of the most frequent oral adverse drug reactions has been reported to be xerostomia, which is commonly known to include dry mouth, dysgeusia (distortion in sense of taste), and stomatitis (inflammation in oral mucosal tissue). People suffering from dry mouth may experience reduced quality of life and health attributable to the related difficulties in chewing, swallowing, and speaking. Patients with a dry mouth may complain of associated dryness of the lips and throat, oral soreness or burning, altered taste sensations and halitosis (bad breath). Moreover, the lack of an adequate salivary film between dentures and underlying gums can impair retention of dentures, and the lack of salivary lubrication can lead to denture induced mucosal ulceration. Saliva acts to buffer organic acids produced by dental plaque and maintains a demineralizing environment within the oral cavity to preserve the teeth. A reduction in salivary flow rates is therefore thought to increase the risk of dental caries. Patients with a dry mouth will often try to alleviate their symptoms by sucking sweet confectionery, chewing sugar containing gums or by drinking cariogenic and acidic beverages. All of these can further increase the risk of tooth surface demineralization and caries. Scientific literature demonstrates that people taking three or more prescription medications had a higher Root Caries Index (RCI) than those taking none, one or two drugs, and people who took antidepressants and antiulcer drugs had highest RCI values. Other consequences of oral dryness and reduced unstimulated salivary flow were significantly associated with depression, trait anxiety, perceived stress, state anxiety, female gender, and intake of antihypertensives. Age and medication seemed to play a more important role in individuals with objective evidence of hyposalivation. Medication is, however, a better predictor of risk status for dry mouth than either age or gender. Cannabinoids are a group of chemicals found in Cannabis sativa, Cannabis indica, Cannabis ruderalis, Marijuana plant and related plant species. They are known to activate cannabinoid receptors (CB1 and CB2). These chemicals are also produced endogenously in humans and other animals. Cannabinoids are cyclic molecules exhibiting particular properties such as being lipophilic, have the ability to easily cross the blood-brain barrier, and having low toxicity. Cannabis sativa contains more than 400 chemicals and approximately 120 cannabinoids, the active constituents of cannabis, including cannabidiol (CBD). The main purpose of administering cannabidiol to patients in need thereof has been to treat or alleviate a wide range of medical conditions in the human body. Hitherto, however, there has been very little focus on benefits in a combined use of cannabidiol with other drugs, such as drugs that may cause xerostomia. The drugs most implicated in dry mouth include anticholinergics, sympathomimetic drugs, benzodiazepines, anti-migraine agents. These drugs include, but are not limited to, antihypertensives (e.g., beta blockers), antipsychotics, tricyclic antidepressants, atropines, and antihistamines. Dry mouth may be caused by salivary gland hypofunction including hyposalivation and changes in salivary constituents. In turn, this may alter the threshold for the perception of dry mouth. Older patients appear to be more at risk of a drug-induced dry mouth, with greater salivary gland hypofunction, compared to younger adults. This may be attributed to higher frequency of polypharmacy in older adults. The mechanisms and control of salivary secretion have been fully reviewed in the prior art. Salivary gland secretion is mainly under autonomic nervous control, although various hormones may also modulate the salivary composition. Acetylcholine released by the parasympathetic nervous system stimulates muscarinic acetylcholine receptors (mAChRs) on salivary secretory cells and triggers the secretion of serous saliva. For instance, the mAChRs agonist, Salagen, is currently used to treat people suffering from Sjögrens disease. Accordingly, there is a need in the prior art for drugs that may alleviate or treat xerostomia, such as xerostomia caused by other drugs as described above. Additionally, there is a need in the prior art for drugs that to a certain extent may counteract or reverse the effect of xerostomia caused by other drugs as described above. More particularly, there is an unmet need of a drug that may reverse the decrease of acetylcholine and thereby counteract the effect of xerostomia for commonly used drugs. SUMMARY OF THE INVENTION Accordingly, there is provided a method of alleviating or treating xerostomia in patients in need thereof by the use of cannabidiol. The invention benefits from a synergy of the advantage that cannabidiol provides to certain medical conditions in the human body and the advantage of alleviating or treating xerostomia according to the invention. Furthermore, the invention may counteract or reverse the effects of xerostomia induces by other drugs, such as anticholinergics, sympathomimetic drugs, benzodiazepines, anti-migraine agents, which was highly surprising to the inventors. In this context, the cannabidiol may be administered at the same time, relatively shortly before or after administration of the drug that induces xerostomia. Hence, the cannabidiol may in one extreme be administered as the first compound to prevent or decrease hyposalivation, whereafter the drug that induces xerostomia may be administered afterwards in order to keep a certain amount of saliva during administration of this drug and prevent xerostomia. In the other extreme, the drug that induces xerostomia may be administered first, whereafter cannabidiol may be administered afterwards. The invention may also serve to alleviate or treat oral as well as dental diseases or disorders. Another advantage is that the formulation according to the invention may also help in obtaining improved sensorics properties of oral cannabidiol delivery. Here, important sensorics properties include texture, flavor perception, sweetness perception and off- notes. These properties are both relevant from a convenience perspective when cannabidiol is formulated in solid dosage forms, but certainly also in order to support an appropriate delivery of cannabidiol from solid dosage forms, such as tablets, and avoid adverse side effects of cannabidiol. The spirit of the invention is to apply cannabidiol as the only cannabinoid in the alleviation or treatment of xerostomia. Hence, the invention does not attempt to rely on a combination of different cannabinoids to achieve the effect, but solely on the effect of cannabidiol as such. Accordingly, it is the effect of cannabidiol as the sole cannabinoid that is intended to contribute to alleviating or treating xerostomia. In the present context, “alleviating and treating” or similar wordings is intended to imply that xerostomia is completely diminished or suppressed, or that the condition is alleviated so that the condition is less pronounced. Minor amounts of other cannabinoids may be present, but also higher amounts of other cannabinoids may be present for other purposes than treating or alleviating the condition. Additionally, the administration of cannabidiol is not intended to work in combination with other active ingredients that do not cause xerostomia in order to achieve the desired effect, such as certain analgesics. In the present context, “saliva generation” may be applied as a means for identifying the effect of xerostomia, i.e., if more saliva is generated compared to a situation where the cannabinoid is not applied, an increase in the total amount of saliva generated may be taken as an indication of improvement. In some embodiments of the invention, the cannabidiol is administered orally, such as by peroral administration or by sublingual administration. In some embodiments of the invention, the cannabidiol is administered in a unit dose of 10 to 500 mg cannabidiol. In some embodiments of the invention, the cannabidiol is administered in a unit dose of 50 to 500 mg cannabidiol. In some embodiments of the invention, the cannabidiol is administered in a unit dose of 75 to 500 mg cannabidiol. In some embodiments of the invention, the cannabidiol is administered in a unit dose of 100 to 500 mg cannabidiol. In some embodiments of the invention, the cannabidiol is administered in a unit dose of 150 to 500 mg cannabidiol. In some embodiments of the invention, the cannabidiol is administered in a unit dose of 20 to 400 mg cannabidiol. In some embodiments of the invention, the cannabidiol is administered in a unit dose of 50 to 400 mg cannabidiol. In some embodiments of the invention, the cannabidiol is administered in a unit dose of 75 to 400 mg cannabidiol. In some embodiments of the invention, the cannabidiol is administered in a unit dose of 100 to 400 mg cannabidiol. In some embodiments of the invention, the cannabidiol is administered in a unit dose of 150 to 400 mg cannabidiol. In some embodiments of the invention, the cannabidiol is administered in a unit dose of 50 to 200 mg cannabidiol. In some embodiments of the invention, the cannabidiol is administered in a unit dose of 50 to 300 mg cannabidiol. In some embodiments of the invention, the cannabidiol is administered in a unit dose of 75 to 200 mg cannabidiol. In some embodiments of the invention, the cannabidiol is administered in a unit dose of 75 to 300 mg cannabidiol. In some embodiments of the invention, the cannabidiol is administered in a unit dose of 100 to 300 mg cannabidiol. In some embodiments of the invention, the cannabidiol is administered in a unit dose of 150 to 300 mg cannabidiol. In some embodiments of the invention, the cannabidiol is administered in one dose per day. In some embodiments of the invention, the cannabidiol is administered in two doses per day. In some embodiments of the invention, the cannabidiol is administered in three doses per day. In some embodiments of the invention, the cannabidiol is administered in four doses per day. In some embodiments of the invention, the cannabidiol is administered in a dosing interval of 4 to 8 hours, such as about 6 hours. In some embodiments of the invention, the cannabidiol is administered in a dosing interval of 10 to 14 hours, such as about 12 hours. In some embodiments of the invention, the cannabidiol is administered in a dosing interval of 16 to 20 hours, such as about 18 hours. In some embodiments of the invention, the cannabidiol is administered in a dosing interval of 22 to 26 hours, such as about 24 hours. In some embodiments of the invention, the cannabidiol is administered for a period of at least 7 days, such as at least 14 days, such as at least 21 days, such as at least 30 days. In some embodiments of the invention, the cannabidiol is administered on a permanent basis. In some embodiments of the invention, the cannabidiol induces saliva secretion. Hence, in this respect, xerostomia may alleviate or treat xerostomia by promoting saliva secretion. In some embodiments of the invention, saliva secretion is increased by at least 10% in the alleviation or treatment of xerostomia, such as at least 20%, such as at least 30%, such as at least 50%. In some embodiments of the invention, saliva secretion is increased by at least 15% in the alleviation or treatment of xerostomia. In some embodiments of the invention, saliva secretion is increased by at least 20% in the alleviation or treatment of xerostomia. In some embodiments of the invention, saliva secretion is increased by at least 25% in the alleviation or treatment of xerostomia. In some embodiments of the invention, saliva secretion is increased by at least 30% in the alleviation or treatment of xerostomia. In some embodiments of the invention, saliva secretion is increased by at least 40% in the alleviation or treatment of xerostomia. In some embodiments of the invention, saliva secretion is increased by at least 75% in the alleviation or treatment of xerostomia. In some embodiments of the invention, saliva secretion is increased by at least 100% in the alleviation or treatment of xerostomia. In the present context, “saliva secretion” is intended to be based on the total amount of saliva generated compared to a situation where cannabidiol is not administered. In some embodiments of the invention, xerostomia is associated with salivary gland hypofunction. In some embodiments of the invention, the alleviation or treatment of xerostomia involves stimulation of acetylcholine receptors (mAChRs) on salivary secretory cells. In some embodiments of the invention, the cannabidiol acts as a CB1 receptor antagonist. In some embodiments of the invention, the cannabidiol is administered in a dosage regimen comprising a drug that causes xerostomia. In some embodiments of the invention, the cannabidiol is administered together with a drug that causes xerostomia. In some embodiments of the invention, the cannabidiol is administered to counteract a drug that causes xerostomia. In some embodiments of the invention, the cannabidiol is administered to counteract a drug that causes xerostomia selected from the group consisting of anticholinergic drugs, sympathomimetic drugs, benzodiazepines, anti-migraine agents, and combinations thereof. In some embodiments of the invention, the cannabidiol according to the invention is the active ingredient alleviating or treating xerostomia without other active ingredients having the same effect or function. In some embodiments of the invention, the cannabidiol according to the invention is the active ingredient alleviating or treating xerostomia without other active ingredients having the same effect or function. In some embodiments of the invention, the cannabidiol is not administered with other active ingredients that do not cause xerostomia, such as analgesics that does not cause xerostomia. In some embodiments of the invention, the cannabidiol according to the invention is administered as the only cannabinoid for alleviating or treating xerostomia. In some embodiments of the invention, the cannabidiol according to the invention is administered as the only major cannabinoid for alleviating or treating xerostomia. In some embodiments of the invention, the cannabidiol according to the invention is administered without a major amount of other cannabinoids, such as THC. In the present context, “major” is intended to mean present in an amount of more than 10% by weight of the cannabidiol. In some embodiments of the invention, the cannabidiol is a CB1 receptor antagonist In some embodiments of the invention, the cannabidiol is a CB1 receptor antagonist that prevents reduction of acetylcholine release by a drug that causes xerostomia. In some embodiments of the invention, the cannabidiol is further applied for alleviating or treating inflammatory conditions in the oral cavity. In some embodiments of the invention, the cannabidiol is further applied as an anti- microbial treatment. In some embodiments of the invention, the cannabidiol is further applied to treat caries. In some embodiments of the invention, the cannabidiol is further applied as an oral care agent. In some embodiments of the invention, the cannabidiol is further administered with oral care agents. In some embodiments of the invention, the cannabidiol is present in a purity of at least 90% (w/w), such as at least 95% (w/w), such as at least 98% (w/w). In some embodiments of the invention, the cannabidiol is an isolated cannabidiol. In some embodiments of the invention, the cannabidiol does not include cannabidiol extract or cannabidiol distillates. In some embodiments of the invention, the cannabidiol does not include cannabidiol in a purity of less than 90% (w/w). In some embodiments of the invention, a solid dosage form is provided that comprises cannabidiol for use in the alleviation or treatment of xerostomia. Solid forms may include capsules, such as gel capsules (for peroral delivery), and pastilles, such as soft lozenges not made by compression. In some embodiments of the invention, a solid dosage form is provided that comprises cannabidiol in an amount of at least 5% by weight of the solid dosage form, such as at least 10% by weight of the solid dosage form, such as at least 20% by weight of the solid dosage form, such as at least at least 30% by weight of the solid dosage form. In some embodiments of the invention, a solid dosage form is provided that comprises triglycerides in an amount of 1.0 to 25.0% by weight of the solid dosage form. In some embodiments of the invention, a solid dosage form is provided that comprises triglycerides in an amount of 1.0 to 20.0% by weight of the solid dosage form. In some embodiments of the invention, a solid dosage form is provided that comprises triglycerides in an amount of 1.0 to 10.0% by weight of the solid dosage form. In some embodiments of the invention, a solid dosage form is provided that comprises triglycerides in an amount of 1.0 to 5.0% by weight of the solid dosage form. In some embodiments of the invention, a solid dosage form is provided that comprises triglycerides in an amount of 2.0 to 25.0% by weight of the solid dosage form. In some embodiments of the invention, a solid dosage form is provided that comprises triglycerides in an amount of 2.0 to 20.0% by weight of the solid dosage form. In some embodiments of the invention, a solid dosage form is provided that comprises triglycerides in an amount of 2.0 to 10.0% by weight of the solid dosage form. In some embodiments of the invention, a solid dosage form is provided that comprises triglycerides in an amount of 2.0 to 5.0% by weight of the solid dosage form. In some embodiments of the invention, a solid dosage form is provided that comprises triglycerides in an amount of more than 1.0% by weight of the solid dosage form. In some embodiments of the invention, a solid dosage form is provided that comprises triglycerides in an amount of more than 2.0% by weight of the solid dosage form. In some embodiments of the invention, a solid dosage form is provided that comprises triglycerides in an amount of more than 5.0% by weight of the solid dosage form. In some embodiments of the invention, a solid dosage form is provided that comprises triglycerides in an amount of more than 10.0% by weight of the solid dosage form. In some embodiments of the invention, a solid dosage form is provided that comprises triglycerides in an amount of more than 15.0% by weight of the solid dosage form. In some embodiments of the invention, a solid dosage form is provided that comprises triglycerides in an amount of less than 25.0% by weight of the solid dosage form. In some embodiments of the invention, a solid dosage form is provided that comprises triglycerides in an amount of less than 20.0% by weight of the solid dosage form. In some embodiments of the invention, a solid dosage form is provided that comprises triglycerides in an amount of less than 15.0% by weight of the solid dosage form. In some embodiments of the invention, a solid dosage form is provided that comprises triglycerides in an amount of less than 10.0% by weight of the solid dosage form. In some embodiments of the invention, a solid dosage form is provided that comprises triglycerides in an amount of less than 5.0% by weight of the solid dosage form. In some embodiments of the invention, a solid dosage form is provided that comprises bulk sweeteners in an amount of 10 to 90% by weight of the solid dosage form. In some embodiments of the invention, a solid dosage form is provided that comprises bulk sweeteners in an amount of 20 to 90% by weight of the solid dosage form. In some embodiments of the invention, a solid dosage form is provided that comprises bulk sweeteners in an amount of 20 to 80% by weight of the solid dosage form. In some embodiments of the invention, a solid dosage form is provided that comprises bulk sweeteners in an amount of 30 to 80% by weight of the solid dosage form. In some embodiments of the invention, a solid dosage form is provided that comprises bulk sweeteners in an amount of 30 to 70% by weight of the solid dosage form. In some embodiments of the invention, a solid dosage form is provided that comprises bulk sweeteners in an amount of 35 to 70% by weight of the solid dosage form. In some embodiments of the invention, a solid dosage form is provided that comprises bulk sweeteners in an amount of at least 10% by weight of the solid dosage form. In some embodiments of the invention, a solid dosage form is provided that comprises bulk sweeteners in an amount of at least 20% by weight of the solid dosage form. In some embodiments of the invention, a solid dosage form is provided that comprises bulk sweeteners in an amount of at least 30% by weight of the solid dosage form. In some embodiments of the invention, a solid dosage form is provided that comprises bulk sweeteners in an amount of at least 40% by weight of the solid dosage form. In some embodiments of the invention, a solid dosage form is provided that comprises bulk sweeteners in an amount of at least 50% by weight of the solid dosage form. In some embodiments of the invention, a solid dosage form is provided that comprises bulk sweeteners in an amount of at least 60% by weight of the solid dosage form. In some embodiments of the invention, a solid dosage form is provided that comprises bulk sweeteners in an amount of at least 70% by weight of the solid dosage form. In some embodiments of the invention, a solid dosage form is provided that comprises bulk sweeteners in an amount of at least 80% by weight of the solid dosage form. In the present context, “bulk sweeteners” may include sugar-free components, sugar alcohols, polyols, or sugars. In some embodiments of the invention, a solid dosage form is provided that comprises sugar alcohols selected from the group consisting of sorbitol, xylitol, maltitol, isomalt, mannitol, erythritol, lactitol, and combinations thereof. In some embodiments of the invention, a solid dosage form is provided that comprises one or more saccharides. In some embodiments of the invention, a solid dosage form is provided that comprises further ingredients selected from the group consisting of flavors, dry-binders, tableting aids, anti-caking agents, surfactants, emulsifiers, antioxidants, enhancers, mucoadhesives, absorption enhancers, high intensity sweeteners, softeners, colors, further active ingredients, water-soluble indigestible polysaccharides, water-insoluble polysaccharides, and combinations thereof. In some embodiments of the invention, a solid dosage form is provided that comprises one or more insoluble components selected from the group consisting of silica, microcrystalline cellulose, cellulose, silicified microcrystalline cellulose, clay, talc, starch, pregelatinized starch, calcium carbonate, dicalcium phosphate, magnesium carbonate, magnesium-alumino-metasilicates, hyper porous silica, and mixtures thereof. In some embodiments of the invention, a solid dosage form is provided that comprises microcrystalline cellulose. In some embodiments of the invention, a tablet is provided that comprises directly compressible (DC) sugar alcohol particles and non-directly compressible (non-DC) sugar alcohol particles. This embodiment is believed to be particularly advantageous since the combination of the two types of sugar alcohol particles may provide a salivation stimulating effect, which may work in synergy with the effects of cannabidiol according to the invention. In some embodiments of the invention, a tablet is provided that comprises directly compressible (DC) sugar alcohol particles and non-directly compressible (non-DC) sugar alcohol particles in a ratio between 0.2 and 1.2, such as a ratio between 0.3 and 0.7. In some embodiments of the invention, a tablet is provided that comprises one or more binders in an amount of 0.1 to 6% by weight of the tablet. In some embodiments of the invention, a tablet is provided that comprises at least two modules. In some embodiments of the invention, a tablet is provided that comprises at least two modules, and wherein the tablet comprises directly compressible (DC) sugar alcohol particles and non-directly compressible (non-DC) sugar alcohol particles located in the same module. In some embodiments of the invention, a tablet is provided that comprises directly compressible (DC) sugar alcohol particles and non-directly compressible (non-DC) sugar alcohol particles, and wherein the non-directly (non-DC) sugar alcohol particles are selected from the group consisting of non-directly (non-DC) sugar alcohol particles of xylitol, maltitol, isomalt, mannitol, erythritol, lactitol, and combinations thereof. In some embodiments of the invention, a tablet is provided that comprises directly compressible (DC) sugar alcohol particles and non-directly compressible (non-DC) sugar alcohol particles, and wherein the non-directly (non-DC) sugar alcohol particles are selected from the group consisting of non-directly (non-DC) sugar alcohol particles of xylitol, maltitol, isomalt, mannitol, lactitol, and combinations thereof. In some embodiments of the invention, a tablet is provided that comprises directly compressible (DC) sugar alcohol particles and non-directly compressible (non-DC) sugar alcohol particles, and wherein the non-directly (non-DC) sugar alcohol particles are selected from the group consisting of non-directly (non-DC) sugar alcohol particles of xylitol, maltitol, isomalt, lactitol, and combinations thereof. In some embodiments of the invention, a tablet is provided that comprises directly compressible (DC) sugar alcohol particles and non-directly compressible (non-DC) sugar alcohol particles, and wherein the non-directly (non-DC) sugar alcohol particles are selected from the group consisting of non-directly (non-DC) sugar alcohol particles of xylitol, maltitol, isomalt, erythritol and combinations thereof. In some embodiments of the invention, a tablet is provided that comprises directly compressible (DC) sugar alcohol particles and non-directly compressible (non-DC) sugar alcohol particles, and wherein the non-directly (non-DC) sugar alcohol particles are selected from the group consisting of non-directly (non-DC) sugar alcohol particles of xylitol, maltitol, isomalt, and combinations thereof. In some embodiments of the invention, a tablet is provided that comprises directly compressible (DC) sugar alcohol particles and non-directly compressible (non-DC) sugar alcohol particles, and wherein the directly (DC) sugar alcohol particles are selected from the group consisting of directly (DC) sugar alcohol particles of sorbitol, xylitol, maltitol, isomalt, mannitol, erythritol, lactitol, and combinations thereof. In some embodiments of the invention, a tablet is provided that comprises directly compressible (DC) sugar alcohol particles and non-directly compressible (non-DC) sugar alcohol particles, and wherein the directly (DC) sugar alcohol particles are selected from the group consisting of directly (DC) sugar alcohol particles of sorbitol, xylitol, maltitol, isomalt, erythritol, and combinations thereof. In some embodiments of the invention, a tablet is a chewable tablet. In some embodiments of the invention, a chewable tablet is provided that comprises directly compressible (DC) sugar alcohol particles and non-directly compressible (non-DC) sugar alcohol particles. One of the advantages of combining non-DC and DC sugar alcohol particles in the present invention is that a further synergy is provided in terms of saliva generation. Whereas, non-DC sugar alcohol particles are known to increase the saliva generation, the extra benefit is that this combined with the presence of cannabidiol may provide even further benefits for patients in need thereof. In some embodiments of the invention, a chewable tablet is provided that has a weight ratio between said non-DC sugar alcohol particles and said DC sugar alcohol particles, which is between 0.2 and 1.2. In some embodiments of the invention, a chewable tablet is provided that has a weight ratio between said non-DC sugar alcohol particles and said DC sugar alcohol particles, which is between 0.3 and 0.7. In some embodiments of the invention, a chewable tablet is provided that comprises one or more insoluble components selected from the group consisting of silica, microcrystalline cellulose, cellulose, silicified microcrystalline cellulose, clay, talc, starch, pregelatinized starch, calcium carbonate, dicalcium phosphate, magnesium carbonate, magnesium-alumino-metasilicates, hyper porous silica, and mixtures thereof. In some embodiments of the invention, a chewable tablet is provided that comprises one or more binders in an amount of 0.1 to 6% by weight of the tablet. In some embodiments of the invention, a tablet is provided that comprises one or more binders in an amount of 0.1 to 8%, such as 0.1 to 7%, such as 1 to 7%, such as 2 to 7%, such as 0.1 to 6%, such as 1 to 6% by weight of the tablet. In some embodiments of the invention, a tablet is provided that comprises at least two modules, and wherein a premixture is comprised in at least one module of the tablet. In some embodiments of the invention, a tablet is provided that comprises further ingredients selected from the group consisting of flavors, dry-binders, tableting aids, anti-caking agents, surfactants, emulsifiers, antioxidants, enhancers, mucoadhesives, absorption enhancers, high intensity sweeteners, softeners, colors, further active ingredients, water-soluble indigestible polysaccharides, water-insoluble polysaccharides, and any combination thereof. In some embodiments of the invention, a chewing gum is provided that comprises gum base in an amount of 20-40% by weight of the chewing gum, and wherein the chewing gum is designed to be masticated into a coherent residual containing water-insoluble components. By applying chewing gum as a delivery vehicle for the cannabidiol according to the invention, a synergy is established. Saliva generation is further promoted with chewing gum as the delivery vehicle. In some embodiments of the invention, a chewing gum is provided that comprises gum base, and wherein the gum base comprises an elastomer selected from the group consisting of styrene-butadiene rubber (SBR), butyl rubber, polyisobutylene (PIB), and combinations thereof. In some embodiments of the invention, a chewing gum is provided that comprises gum base, and wherein the gum base comprises at least 5% by weight of elastomer. In some embodiments of the invention, a chewing gum is provided that comprises gum base, and wherein the gum base comprises gum base resins selected from natural resins and/or synthetic resins. In some embodiments of the invention, a chewing gum is provided that comprises gum base, and wherein the gum base comprises at least 5% by weight of gum base resins. In some embodiments of the invention, a chewing gum is provided that comprises at least two compressed modules. In some embodiments of the invention, a chewing gum is provided that comprises at least two compressed modules, and wherein the two modules are different in composition. In some embodiments of the invention, a chewing gum is provided that comprises at least two compressed modules, and wherein at least one of the two compressed modules does not comprise gum base. In some embodiments of the invention, a chewing gum is provided that comprises gum base, and wherein the gum base comprises gum base particles having an average particle size of between 400µm and 1400µm. In some embodiments of the invention, a chewing gum is provided that comprises one or more sugar alcohols in addition to the one or more sweeteners in the premixture selected from the group consisting of sorbitol, erythritol, maltitol, xylitol, isomalt, lactitol, mannitol, and combinations thereof. In some embodiments of the invention, a series of at least 10 compressed chewing gums comprise cannabidiol in an amount varying with a relative standard deviation (RSD) below 5%. Generally, the method used for content uniformity of cannabidiol in compressed chewing gums is determined according to European Pharmacopoeia 10.8 when using test method 2.9.40. Uniformity of dosage units. The acceptance value (AV) is calculated using mass variation (MV) or content uniformity (CU) depending on the dose and ratio of the drug substance. An appropriate analytical method is selected for content uniformity. In some embodiments of the invention, a series of at least 10 compressed chewing gums comprise cannabidiol in an amount varying with a relative standard deviation (RSD) below 2%. In some embodiments of the invention, the chewing gum comprises at least two compressed modules, and wherein the premixture is comprised in at least one of the two compressed modules. In some embodiments of the invention, a chewing gum is provided that comprises further ingredients selected from the group consisting of flavors, dry-binders, tableting aids, anti-caking agents, surfactants, emulsifiers, antioxidants, enhancers, mucoadhesives, absorption enhancers, high intensity sweeteners, softeners, colors, further active ingredients, water-soluble indigestible polysaccharides, water- insoluble polysaccharides, and any combination thereof. In some embodiments of the invention, a lozenge is provided that comprises one or more disintegrants operable to disintegrate the lozenge within a period of 3 minutes or less in contact with oral saliva. In some embodiments of the invention, a lozenge is provided that comprises one or more disintegrants operable to disintegrate the lozenge within a period of 2 minutes or less in contact with oral saliva. In some embodiments of the invention, a lozenge is provided that comprises one or more disintegrants operable to disintegrate the lozenge within a period of 1 minute or less in contact with oral saliva. In some embodiments of the invention, a lozenge is provided that comprises one or more dissolution modifiers. In some embodiments of the invention, a lozenge is provided that comprises one or more dissolution modifiers operable to disintegrate the lozenge within a period of 5 minutes or more in contact with oral saliva. In some embodiments of the invention, a lozenge is provided that comprises one or more dissolution modifiers operable to disintegrate the lozenge within a period of 10 minutes or more in contact with oral saliva. In some embodiments of the invention, a lozenge is provided that comprises one or more dissolution modifiers operable to disintegrate the lozenge within a period of 15 minutes or more in contact with oral saliva. In some embodiments of the invention, a lozenge is provided that comprises one or more dissolution modifiers operable to disintegrate the lozenge within a period of 20 minutes or more in contact with oral saliva. In some embodiments of the invention, a lozenge is provided that comprises one or more dissolution modifiers selected from the group of alginates and xanthan gum. In some embodiments of the invention, a lozenge is provided that comprises one or more dissolution modifiers in an amount of 1-5% by weight of the lozenge. In some embodiments of the invention, a lozenge is provided that comprises one or more disintegrants selected from the group consisting of crosslinked cellulose (eg. sodium croscarmellose), crosslinked polyvinyl pyrrolidone (eg. crospovidone), crosslinked starch (eg. sodium starch glycolate), and combinations thereof. In some embodiments of the invention, a lozenge is provided that comprises one or more disintegrants in an amount of 0.5 to 25% by weight of the lozenge. In some embodiments of the invention, a lozenge is provided that comprises one or more disintegrants in an amount of 1 to 10% by weight of the lozenge. In some embodiments of the invention, a series of at least 10 lozenges comprise cannabidiol in an amount varying with a relative standard deviation (RSD) below 5%. Generally, the method used for content uniformity of lozenges is determined according to European Pharmacopoeia 10.8 when using test method 2.9.40. Uniformity of dosage units. The acceptance value (AV) is calculated using mass variation (MV) or content uniformity (CU) depending on the dose and ratio of the drug substance. An appropriate analytical method is selected for content uniformity. In some embodiments of the invention, a series of at least 10 lozenges comprise cannabidiol in an amount varying with a relative standard deviation (RSD) below 2%. In some embodiments of the invention, a lozenge is provided that comprises one or more sugar alcohols in addition to the one or more sweeteners in the premixture selected from the group consisting of sorbitol, erythritol, maltitol, xylitol, isomalt, lactitol, mannitol, and combinations thereof. In some embodiments of the invention, a lozenge is provided that comprises one or more sweeteners in addition to the one or more sweeteners in the premixture in an amount of 20 to 60% by weight of the lozenge. In some embodiments of the invention, a lozenge is provided that comprises one or more insoluble components selected from the group consisting of silica, microcrystalline cellulose, cellulose, silicified microcrystalline cellulose, clay, talc, starch, pregelatinized starch, calcium carbonate, dicalcium phosphate, magnesium carbonate, magnesium-alumino-metasilicates, hyper porous silica, and mixtures thereof. In some embodiments of the invention, a lozenge is provided that comprises one or more disintegrants selected from the group consisting of sodium croscarmellose, crospovidone, sodium starch glycolate, and combinations thereof. In some embodiments of the invention, a lozenge is provided that comprises further ingredients selected from the group consisting of flavors, dry-binders, tableting aids, anti-caking agents, surfactants, emulsifiers, antioxidants, enhancers, mucoadhesives, absorption enhancers, high intensity sweeteners, softeners, colors, further active ingredients, water-soluble indigestible polysaccharides, water-insoluble polysaccharides, and any combination thereof. In some embodiments of the invention, a pouch is provided that comprises one or more insoluble components selected from the group consisting of silica, clay, talc, starch, pregelatinized starch, calcium carbonate, dicalcium phosphate, magnesium carbonate, magnesium-alumino-metasilicates, hyper porous silica and mixtures thereof. In some embodiments of the invention, a pouch is provided that comprises one or more insoluble fibres. In some embodiments of the invention, a pouch is provided that comprises one or more insoluble fibres selected from wheat fibers, pea fibers, rice fiber, maize fibers, oat fibers, tomato fibers, barley fibers, rye fibers, sugar beet fibers, buckwheat fibers, potato fibers, cellulose fibers, apple fibers, cocoa fibers, cellulose fibers, bran fibers, bamboo fibers, powdered cellulose, microcrystalline cellulose, and combinations thereof. In some embodiments of the invention, a series of at least 10 pouches comprise cannabidiol in an amount varying with a relative standard deviation (RSD) below 5%. Generally, the method used for content uniformity of pouches is determined according to European Pharmacopoeia 10.8 when using test method 2.9.40. Uniformity of dosage units. The acceptance value (AV) is calculated using mass variation (MV) or content uniformity (CU) depending on the dose and ratio of the drug substance. An appropriate analytical method is selected for content uniformity. In some embodiments of the invention, a series of at least 10 pouches comprise cannabidiol in an amount varying with a relative standard deviation (RSD) below 2%. In some embodiments of the invention, a pouch is provided that comprises one or more insoluble components selected from the group consisting of silica, clay, talc, starch, pregelatinized starch, calcium carbonate, dicalcium phosphate, magnesium carbonate, magnesium-alumino-metasilicates, hyper porous silica and mixtures thereof. In some embodiments of the invention, a pouch is provided that comprises one or more sugar alcohols in addition to the one or more sweeteners in the premixture selected from the group consisting of sorbitol, erythritol, maltitol, xylitol, isomalt, lactitol, mannitol, and combinations thereof. In some embodiments of the invention, a pouch is provided that comprises one or more sweeteners in addition to the one or more sweeteners in the premixture in an amount of 20 to 60% by weight of the pouch. In some embodiments of the invention, a pouch is provided that comprises further ingredients selected from the group consisting of flavors, dry-binders, anti-caking agents, surfactants, emulsifiers, antioxidants, enhancers, mucoadhesives, absorption enhancers, high intensity sweeteners, softeners, colors, further active ingredients, water-soluble indigestible polysaccharides, water-insoluble polysaccharides, and any combination thereof. In some embodiments of the invention, a method of treating or alleviating xerostomia in patients in need thereof is provided by administering an effective amount of cannabidiol. In some embodiments of the invention, a method of treating or alleviating xerostomia in patients in need thereof is provided wherein the method includes cannabidiol as formulated in any of the embodiments of the invention. In some embodiments of the invention, the isolated cannabidiol is present in a purity of at least 90% (w/w). In some embodiments of the invention, the one or more isolated cannabidiol is present in a purity of at least 95% (w/w). In some embodiments of the invention, the isolated cannabidiol is present in a purity of at least 98% (w/w). In some embodiments of the invention, the isolated cannabidiol does not include cannabinoid distillates. In some embodiments of the invention, the isolated cannabidiol does not include cannabinoid extracts. In some embodiments of the invention, the isolated cannabidiol does not include isolated cannabidiol in a purity of less than 90% (w/w). In some embodiments of the invention, the isolated cannabidiol is dissolved in triglycerides before admixture with a sweetener powder composition. In some embodiments of the invention, the isolated cannabidiol is added in a sweetener powder composition before admixture with the triglycerides. In some embodiments of the invention, triglycerides are added in a sweetener powder composition before admixture with the isolated cannabidiol. Generally, when it is mentioned that further ingredients are “added in the premixture” or similar wordings, the intended meaning is that these ingredients are added to the total mixture. Hence, a premixture could also be added to the further ingredients depending on the procedure and amounts involved. Usually, a “premix” or “premixture” are expressions used interchangeably. In an embodiment of the invention, oral care agents are applied in combination with cannabidiol comprising one or more anti-plaque agents. Anti-plaque agents include fluoride ion sources. Anti-plaque agents are any substance which by itself acts to inhibit the accumulation of bacterial deposits on the surfaces of the oral cavity. Examples include xylitol and other anti-microbial agents. The inhibition effects of the xylitol on oral microbes may have better effect when used in conjunction with an extract since the extract is also acting to disable the microbes. Typical examples of active ingredients that are particularly desirable from considerations of anti-plaque effectiveness, safety and formulation are: Naficillin, oxacillin, vancomycin, clindamycin, erythromycin, trimethoprim- sulphamethoxazole, rifampin, ciprofloxacin, broad spectrum penicillin, amoxicillin, gentamicin, ceftriazoxone, cefotaxime, chloramphenicol, clavunate, sulbactam, probenecid, doxycycline, spectinomycin, cefixime, penicillin G, minocycline, .beta.- lactamase inhibitors; meziocillin, piperacillin, aztreonam, norfloxacin, trimethoprim, ceftazidime, dapsone. Halogenated diphenyl ethers, e.g.2’,4,4’-trichloro-2- hydroxydiphenyl ether (Triclosan), 2,2’-dihydroxy-5,5’-dibromo-diphenyl ether. Haloqenated salicylanilides, e.g.4’,5-dibromosalicylanilide, 3,4’,5-trichloro- salicylanilide, 3,4’,5-tribromo-salicylanilide, 2,3,3’,5-tetrachloro-salicylanilide, 3,3,3’,5-tetrachloro-salicylanilide, 3,5-dibromo-3’-trifluoromethyl-salicylanilide, 5- n-octanoyl-3’-trifluoromethyl-salicylanilide, 3,5-dibromo-4’-trifluoromethyl- salicylanilide, 3,5-dibromo-3’-trifluoromethyl-salicylanilide (Flurophene). Benzoic esters, e.g. methyl-p-hydroxybenzoic ester, ethyl-p-hydroxybenzoic ester, propyl-p- hydroxybenzoic ester, butyl-p-hydroxybenzoic ester. Halogenated carbanilides, e.g. 3,4,4’-trichlorocarbanilide, 3-trifluoromethyl-4,4’-dichlorocarbanilide, or 3,3,4’ – trichlorocarbanilide. Phenolic compounds (including phenol and its homologs, mono- and poly-alkyl and aromatic halo-phenol and their homologs), e.g. phenol, 2- methyl-phenol, 3-methyl-phenol, 4-methyl-phenol, 4-ethyl-phenol, 2,4-dimethyl- phenol, 2,5-dimethyl-phenol, 3,4-dimethyl-phenol, 2,6-dimethyl-phenol, 4-n-propyl- phenol, 4-n-butyl-phenol, 4-n-amyl-phenol, 4-tert-amyl-phenol, 4-n-hexyl-phenol, 4- n-heptyl-phenol, 2-methoxy-4-(2-propenyl)-phenol (Eugenol), 2-isopropyl-5-methyl- phenol (Thymol), mono- and poly-alkyl- and aralkyl-halophenols, methyl-p- chlorophenol, ethyl-p-chlorphenol, n-propyl-p-chlorophenol, n-butyl-p-chlorophenol, n-amyl-p-chlorophenol, sec-amyl-p-chlorophenol, n-hexyl-p-chlorophenol, cyclohexyl-p-chlorophenol, n-heptyl-p-chlorophenol, n-octyl-p-chlorophenol, o- chlorophenol, methyl-o-chlorophenol, ethyl-o-chlorophenol, n-propyl-o- chlorophenol, n-butyl-o-chlorophenol, n-amyl-o-chlorophenol, tert-amyl-o- chlorophenol, n-hexyl-o-chlorophenol, n-heptyl-o-chloropenol, p-chlorophenol, o- benzyl-p-chlorophenol, o-benzyl-m-methyl-p-chlorophenol, o-benzyl-m,m-dimethyl- p-chlorophenol, o-phenylethyl-p-chlorophenol, o-phenylethyl-m-methyl-p- chlorophenol, 3-methyl-p-chlorophenol, 3,5-dimethyl-p-chlorophenol, 6-ethyl-3- methyl-p-chlorophenol, 6-n-propyl-3-methyl-p-chlorophenol, 6-iso-propyl-3-methyl- p-chlorophenol, 2-ethyl-3,5-dimethyl-p-chlorophenol, 6-sec-butyl-3-methyl-p- chlorophenol, 2-iso-propyl-3,5-dimethyl-p-chlorophenol, 6-diethylmethyl-3-methyl- p-chlorophenol, 6-iso-propyl-2-ethyl-3-methyl-p-chlorophenol, 2-sec-amyl-3,5- dimethyl-p-chlorophenol, 2-diethylmethyl-3,5-dimethyl-p-chlorophenol, 6-sec-octyl- 3-methyl-p-chlorophenol, p-bromophenol, methyl-p-bromophenol, ethyl-p- bromophenol, n-propyl-p-bromophenol, n-butyl-p-bromophenol, n-amyl-p- bromophenol, sec-amyl-p-bromophenol, n-hexyl-p-bromophenol, cyclohexyl-p- bromophenol, o-bromophenol, tert-amyl-o-bromophenol, n-hexyl-o-bromophenol, n- propyl-m,m-dimethyl-o-bromophenol, 2-phenyl-phenol, 4-chloro-2-methyl-phenol, 4-chloro-3-methyl-phenol, 4-chloro-3,5-dimethyl-phenol, 2,4-dichloro-3,5-dimethyl- phenol, 3,4,5,6-tetrabromo-2-methylphenol, 5-methyl-2-pentylphenol 4-isopropyl-3- methylphenol 5-chloro-2-hydroxydiphenyl-methane. Resorcinol and its derivatives, e.g. resorcinol, methyl-resorcinol, ethyl-resorcinol, n-propyl-resorcinol, n-butyl- resorcinol, n-amyl-resorcinol, n-hexyl-resorcinol, n-heptyl-resorcinol, n-octyl- resorcinol, n-nonyl-resorcinol, phenyl-resorcinol, benzyl-resorcinol, phenylethyl- resorcinol, phenylpropyl-resorcinol, p-chlorobenzyl-resorcinol, 5-chloro-2,4- dihydroxydiphenyl-methane, 4’-chloro-2,4-dihydroxydiphenyl-methane, 5-bromo- 2,4-dihydroxydiphenyl-methane, 4”-bromo-2,4-dihydroxydiphenyl-methane. Bisphenolic compounds, e.g. bisphenol A, 2,2’-methylene-bis-(4-chlorophenol), 2,2’-methylene-bis-(3,4,6-trichlorophenol) (hexachlorophene), 2,2’-methylene-bis- (4-chloro-6-bromophenol), bis-(2-hydroxy-3,5-dichlorophenyl)-sulfide, bis-(2- hydroxy-5-chlorobenzyl)-sulfide. Illustrative of polyphosphate compounds with plaque-inhibiting properties are dialkali metal and tetraalkali metal pyrophosphate and mixtures thereof in a hydrated or unhydrated form. Illustrative of pyrophosphate salts are Na2H2P2O7, Na4P2O7and K4P2O7. Other suitable polyphosphates include hydrated or unhydrated alkali metal tripolyphosphates such as Na5P3O10and K5P3O10. In an embodiment of the invention the active ingredient comprises one or more Anti- gingivitis agents. Anti-gingivitis agents can be antiinflammatory agents, such as salicylic acid derivatives (e.g. aspirin), paraminophenol derivative (e.g. acetaminophen), indole and indene acetic acids (indo-methacin, sulindac and etodalac), heteroaryl acetic acids (tolmetin, diclofenac and ketorolac), aryl propionic acid derivatives (ibuprofen, naproxen, ketoprofen, fenopren, oxaprozine), anthranilic acids-(mefenamic acid, meclofenamic acid), enolic acids (piroxicam, tenoxicam, phenylbutazone and oxyphenthatrazone), lactic acid bacteria (LAB), Osteopontin (ONP), IG-Lyt, hexefine, Aloe Vera, chlorhexedine, myrrh, or sage. Anti-gingivitis agents also comprise psychotherapeutic agents, such as thorazine, serentil, mellaril, millazine, tindal, permitil, prolixin, trilafon, stelazine, suprazine, taractan, navan, clozaril, haldol, halperon, loxitane, moban, orap, risperdal, alprazolam, chlordiaepoxide, clonezepam, clorezepate, diazepam, halazepam, lorazepam, oxazepam, prazepam, buspirone, elvavil, anafranil, adapin, sinequan, tofranil, surmontil, asendin, norpramin, pertofrane, ludiomil, pamelor, vivactil, prozac, luvox, paxil, zoloft, effexor, welibutrin, serzone, desyrel, nardil, parnate, or eldepryl. In an embodiment of the invention, oral care agents are applied in combination with cannabidiol comprising one or more dental cosmetic ingredients. A dental cosmetic ingredient includes a whitening agent. These are conveniently selected from teeth colour modifying substances that may be considered among the oral care actives useful in the tablet according to the invention. These substance are suitable for modifying the colour of the teeth to satisfy the consumer such as those listed in the CTFA Cosmetic Ingredient Handbook, 3.sup.rd Edition, Cosmetic and Fragrances Association Inc., Washington D.C. (1982), incorporated herein by reference. Specific examples include talc, mica, magnesium carbonate, calcium carbonate, calcium pyrophosphate, Baking soda, Icelandic moss, bamboo, sodium hexa-metaphosphate, magnesium silicate, aluminium magnesium carbonate, silica, titanium dioxide, zinc oxide, red iron oxide, brown iron oxide, yellow iron oxide, black iron oxide, ferric ammonium ferrocyanide, manganese violet, ultramarine, nylon powder, polyethylene powder, methacrylate powder, polystyrene powder, silk powder, crystalline cellulose, starch, titanated mica, iron oxide titanated mica, bismuth oxychloride, and mixtures thereof. Typical levels are from about 0.05% to about 20%, preferably from about 0.1% to about 15% and most preferably from about 0.25% to about 10%, by weight, of the composition. Whitening agents for use herein may also comprise materials that remove or bleach intrinsic or extrinsic stains on or in tooth surfaces. Such substances are selected from the group consisting of the peroxides, metal chlorites, perborates, percarbonates, peroxyacids, persulphates, and combinations thereof. Suitable peroxide compounds include hydrogen peroxide, urea peroxide, calcium peroxide, carbamide peroxide and mixtures thereof. Suitable metal chlorites include calcium chlorite, barium chlorite, magnesium chlorite, lithium chlorite, sodium chlorite and potassium chlorite. Additional bleaching substances may be hypochlorite, and chlorine dioxide. A preferred percarbonate is sodium percarbonate. Preferred persulphates are oxones. The content of these substances is dependent on the available oxygen or chlorine. In an embodiment of the invention, oral care agents are applied in combination with cannabidiol comprising one or more abrasives. Within the scope of the invention, the oral tablet may comprise abrasive. Typical materials include silica gels and precipitates, aluminas, phosphates, and mixtures thereof. Specific examples include dicalcium orthophosphate dihydrate, calcium pyrophosphate, Bamboo, tricalcium phosphate, hydrated alumina, beta calcium pyrophosphate, calcium carbonate, sodium polymetaphosphate, sodium hexametaphosphate, Calgen, Giltex, Quadrafos, Hagan phosphate, micromet, calcium phosphate dibasic, calcium monohydrogen phosphate, dicalcium orthophosphate secondary calcium phosphate, carbonic acid calcium salt, cacti, calcichew, calcidia, citrical, aragonite, calcite, valerite, aluminum oxide, alumina, silicon dioxide, silica, silicic anhydride, and resinous abrasive materials such as particulate condensation products of urea and formaldehyde and others such as disclosed in US Patent No.3,070,510. Mixtures of polishing agents can also be used. The silica polishing materials generally have an average particle size ranging between about 0.1 to about 30 microns; and preferably from about 5 to about 15 microns. The polishing agent can be precipitated silica or silica gels, such as the silica xerogels described in US Patent No.3,538,230 or in US Patent No.3,862,307. Preferred are the silica xeropgels marketed under the name "Syloid" by the W. R. Grace and Company, Davison Chemical Division. Also preferred are the precipitated silica materials such as those marketed by the J. M. Huber Corporation under the trade name "Zeodent", particularly the silica carrying the designation "Zeodent 119". The types of silica dental polishing agents useful in the tablet of the present invention are described in more details in US Patent No.4,340,583. The polishing agents in the tablet according to the invention is generally present in the range from about 6% to about 70%, preferably from about 10% to about 50%, by weight of the tablet. In an aspect of the invention, a solid dosage form for oral administration of cannabidiol is provided comprising a premixture according to the invention. In some embodiments of the invention, a series of at least 10 solid dosage forms comprise cannabidiol in an amount varying with a relative standard deviation (RSD) below 5%. Generally, the method used for content uniformity of samples is determined according to European Pharmacopoeia 10.8 when using test method 2.9.40. Uniformity of dosage units. The acceptance value (AV) is calculated using mass variation (MV) or content uniformity (CU) depending on the dose and ratio of the drug substance. An appropriate analytical method is selected for content uniformity. In some embodiments of the invention, a series of at least 10 solid dosage forms comprise cannabidiol in an amount varying with a relative standard deviation (RSD) below 2%. In an aspect of the invention, a tablet for oral administration of cannabidiol is provided comprising a premixture according to the invention. In some embodiments of the invention, a series of at least 10 tablets comprise the one or more active pharmaceutical ingredients in an amount varying with a relative standard deviation (RSD) below 5%. In some embodiments of the invention, a series of at least 10 tablets comprise the one or more active pharmaceutical ingredients in an amount varying with a relative standard deviation (RSD) below 2%. Generally, the method used for content uniformity of tablets is determined according to European Pharmacopoeia 10.8 when using test method 2.9.40. Uniformity of dosage units. The acceptance value (AV) is calculated using mass variation (MV) or content uniformity (CU) depending on the dose and ratio of the drug substance. An appropriate analytical method is selected for content uniformity. DETAILED DESCRIPTION OF THE INVENTION The verb "to comprise" as is used in this description and in the claims and its conjugations are used in its non-limiting sense to mean that items following the word are included, but items not specifically mentioned are not excluded. In addition, reference to an element by the indefinite article "a" or "an" does not exclude the possibility that more than one of the elements are present, unless the context clearly requires that there is one and only one of the elements. The indefinite article "a" or “an" thus usually means "at least one". Additionally, the words "a" and "an" when used in the present document in connection with the word comprising or containing denote "one or more." The expression “one or more” is intended to mean one, two, three or more. As used herein, the term "approximately" or "about" in reference to a number are generally taken to include numbers that fall within a range of 5%, 10%, 15%, or 20% in either direction (greater than or less than) of the number unless otherwise stated or otherwise evident from the context (except where such number would be less than 0% or exceed 100% of a possible value). As used herein, the term ”%” and “percent” refers to percent by weight, unless otherwise is stated. The term "particle size" relates to the ability of the particles to move through or be retained by sieve holes of a specific size. As used herein, the term “particle size” refers to the average particle size as determined according to European Pharmacopoeia 9.1 when using test method 2.9.38 particle size distribution estimation by analytical sieving, unless otherwise specifically is mentioned. The term “particle” or similar wording is intended to denote a single, discrete composition of solid matter, such as a granule or individual elements in powder, having a certain size that may deviate considerable. In the present context the term “release” refers to the released substance being liberated from the solid dosage form. In some embodiments, the process of releasing a substance corresponds to the substance being dissolved in saliva. The term “release” in the present context is intended to mean tested under “in vivo” conditions, if not stated otherwise. In the present context, when the solid dosage form is masticated, “in vivo” conditions is intended to mean that a sample is masticated with a chewing frequency of 60 chews pr. minute for a certain period of time in a test panel of 8 test persons, if not stated otherwise. These test persons abstain from eating and drinking at least 30 minutes before initiation of any test. The test persons are healthy persons appointed on an objective basis according to specified requirements. By the phrase “texture” is meant a qualitative measure of the properties of the solid dosage form and of the overall mouth-feel experienced by the user during use. Thus, the term “texture” encompasses measurable quantities such as hardness as well as more subjective parameters related to the feel experienced by a user. The term “sustained release” or “extended release” is herein intended to mean prolonged release over time. The term “rapid release” or “quick release” or “high release” is herein intended to mean a higher content released for a given period of time. The term “controlled release” is intended to mean a release of a substance from a solid dosage form by the aid of active use of the solid dosage form in the oral cavity of the subject, whereby the active use is controlling the amount of substance released. In some embodiments, the present invention comprises self-emulsifying agents. A “self-emulsifying agent” is an agent which will form an emulsion when presented with an alternate phase with a minimum energy requirement. In contrast, an emulsifying agent, as opposed to a self-emulsifying agent, is one requiring additional energy to form an emulsion. Due to the poor solubility of certain active ingredients in physiological fluids, it is an unmet need to solubilize cannabidiol upon mixture with the body physiological fluids to facilitate bio-absorption. To overcome low oral bioavailability, various lipid-based drug delivery systems and self-emulsifying systems have been developed. Lipid- based delivery systems and particularly self-emulsifying drug delivery systems (SEDDS) have been demonstrated to increase the solubility, dissolution and bioavailability of many insoluble active ingredients. However, lipid-based and SEDDS delivery systems are very limited by the amount of active ingredient loading that has to be dissolved in the vehicle composition. Higher concentration of active ingredients are obtained using co-solvents, which enable loads of up to 30% in specific cases. Particular challenges are considered to arise in formulating solid dosage forms with SEDDS. For instance, challenges may arise with obtaining a homogenous mixture where variations are avoided and a safe and convenient delivery may be obtained. Also, the general formulation of the solid dosage forms offering convenience to the user need not be compromised which is often the case if precaution is not taken, such as in cases where a high load of active ingredients is needed. Particularly with respect to SEDDS, the formulation of the present invention may provide some clear benefits, both allowing a higher load of active ingredients and at the same time offer improved sensorics properties of the formulation during use. Other advantages are also present. Importantly, the presence of SEDDS or at least a self-emulsifying agent was seen to act in synergy with increased saliva generation. While increased saliva generation was seen to distribute certain active ingredients and allocate a higher load of active ingredients to for instance mucosal surfaces, the presence of SEDDS or at least a self-emulsifying agent was seen to further increase the uptake of these active ingredients through mucosal surfaces. Accordingly, the synergy between the presence of SEDDS or at least a self-emulsifying agent and increased saliva generation according to the invention was a surprise to the inventors. In some embodiments, increased saliva generation may result in a higher exposure of the active ingredients to mucosal surfaces. The presence of SEDDS may work to increase the affinity of the active ingredients from this saliva to the mucosa. Particularly, the potential of SEDDS to have a high load of active ingredients further contributes to the synergy of the solid dosage form according to the invention in combination with improved saliva generation. In the present context, SEDDS is a solid or liquid dosage form comprising an oil phase, a surfactant and optionally a co-surfactant, characterized primarily in that said dosage form can form oil-in-water emulsion spontaneously in the oral cavity or at ambient temperature (referring generally to body temperature, namely 37° C.). When a SEDDS enters the oral cavity or the gastrointestinal tract (GI), it is initially self- emulsified as emulsion droplets and rapidly dispersed, and thus reducing the irritation caused by the direct contact of the active ingredient with the mucous membrane, and hence helping on taste-masking active ingredients. In the oral cavity or the gastrointestinal tract, the structure of the emulsion microparticulate will be changed or destroyed. The resulting microparticulate of micrometer or nanometer level can penetrate into the mucous membrane, and the absorbed oil droplets enter the blood circulation, thereby significantly improving the bioavailability of the active ingredient. In an embodiment of the invention, the self-emulsifying system comprises one or more emulsifiers and one or more oil carriers. In an embodiment of the invention, the self-emulsifying system comprises one or more emulsifiers, one or more oil carriers and one or more solubilizers. In an embodiment of the invention, the self- emulsifying system comprises one or more emulsifiers, one or more oil carriers, one or more solubilizers and one or more solvents. In an embodiment of the invention, the self-emulsifying system comprises one or more emulsifiers and one or more solvents. In an embodiment of the invention, the self-emulsifying system comprises one or more emulsifiers that have both emulsifying and solubilizing properties. In an embodiment of the invention, the self-emulsifying system comprises one or more emulsifiers that act as both an emulsifier and a carrier. In an embodiment of the invention, the self-emulsifying system comprises one or more emulsifiers that act as both an emulsifier, a carrier and a solubilizer. In an embodiment of the invention, the self-emulsifying system comprises one or more fatty acids, one or more glycerols, one or more waxes, one or more flavonoids and one or more terpenes. In an embodiment of the invention, the self-emulsifying system comprises one or more emulsifiers that have an HLB-value of more than 6, preferably of 8-18. In an embodiment of the invention, the one or more emulsifiers are selected from the group consisting of PEG-35 castor oil, PEG-6 oleoyl glycerides, PEG-6 linoleoyl glycerides, PEG-8 caprylic/capric glyceride, sorbitan monolaurate, sorbitan monooleate, polyoxyethylene (20) sorbitan monolaurate, polyoxyethylene (60) sorbitan monostearate, polyoxyethylene (80) sorbitan monooleate, lauroylpoloxyl-32 glycerides, stearoyl polyoxyl-32 glycerides, polyoxyl-32 stearate, propylene glycol mono laurate, propylene glycol di laurate, and mixtures and combinations thereof. In an embodiment of the invention, the one or more emulsifiers comprise PEG-35 castor oil. In an embodiment of the invention, the oil carrier is selected from the group consisting of natural fatty acids; medium-chain triglycerides of caprylic (C8) and capric (C10) acids; propylene glycol esters of caprylic (C8) and capric (C10) acids; mono-, di- and triglycerides of mainly linoleic (C18:2) and oleic (C18:1) acids; fatty acid 18:1 cis-9; natural fatty acids; mono-, di- and triglycerides of oleic (C18:1) acid, and mixtures and combinations thereof. In an embodiment of the invention, the one or more solvents are selected from the group consisting of polyglyceryl-3 dioleate, 1,2-propandiol, polyethylene glycol 300, polyethylene glycol 400, diethylene glycol monoethyl ether, and mixtures and combinations thereof. In an embodiment of the invention, the oil carrier is selected from the group consisting of corn oil, Labrafac lipophile WL1349, Labrafac PG, Maisine CC, oleic acid, olive oil, Peceol, and mixtures and combinations thereof. In an embodiment of the invention, the one or more solvents are selected from the group consisting of polyglyceryl-3 dioleate, 1,2-propandiol, polyethylene glycol 300, polyethylene glycol 400, diethylene glycol monoethyl ether, and mixtures and combinations thereof. In an embodiment of the invention, the one or more solubilizers are selected from the group consisting of lauroylpoloxyl-32 glycerides; stearoyl polyoxyl-32 glycerides; Polyoxyl-32 stearate; synthetic copolymer of ethylene oxide (80) and propylene oxide (27); polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft co- polymer; alpha-, beta- or gamma cyclodextrins and derivatives thereof; pea proteins (globulins, albumins, glutelins proteins); and mixtures and combinations thereof. In some embodiments, the present invention comprises one or more lipids. The term “non-DC sugar alcohol particles” refers to particles of non-directly compressible (non-DC) sugar alcohol. It is noted that the terms “non-DC sugar alcohol particles” and “non-DC particles” are used interchangeably. In the present context, the non-DC sugar alcohol particles refer to particles which have not been preprocessed by granulation with e.g. other sugar alcohols or binders for the purpose of obtaining so-called direct compressible particles (DC). In the present context, non- DC sugar alcohol particles include particles obtained by crystallization followed by milling which does not involve other sugar alcohols or binders. Thus, non-DC sugar alcohol particles are considered as particles consisting of non-DC sugar alcohol. The term “DC sugar alcohol particles” refers to particles of direct compressible (DC) sugar alcohol. It is noted that the terms “DC sugar alcohol particles” and “DC particles” are used interchangeably. DC sugar alcohol particles may be obtained e.g. as particles of sugar alcohols having DC grade by nature, e.g. sorbitol, or by granulating non-DC sugar alcohol with e.g. other sugar alcohols or binders for the purpose of obtaining so-called direct compressible particles (DC). Also, granulation of non-DC sugar alcohol with water as binder is considered to result in “DC sugar alcohol particles” in the present context. The term “tableted” or “tablet” or “compressed” is intended to mean that the tablet composition is pressed in a tableting apparatus and mainly being composed of particulate matter. Although the terms imply a method step, in the present context, the terms are intended to mean the resulting tablet obtained in tableting a portion of particles. It is noted that a tablet or tableted composition that is mentioned to comprise particles eventually is to be understood as particles that have been pressed together in a tableting step. The following description outlines explanations of how the tablet of the invention may be produced and further details of what may be added to the inventive composition. Typically, the process of manufacture of the inventive tablet may be performed in a single tablet press, such as a rotary tablet press. But it may be a benefit under some circumstances to apply a separate tablet press. Preferably, the upper punch is convex which gives the upper face of the pressed tablet a concave form. It should of course be noted that the shape of the punches may vary depending of the desired tablet shape. In some embodiments of the invention, pressing of the tablets are performed at a force of 20 to 50 kN. In one aspect of the invention, the “tablet” is intended to mean a “fast disintegrating tablet” (“FDT”), or similar wording, such as “orally disintegrating tablet” (“ODT”). If not stated otherwise, if the tablet according to the invention is made as one module, contrary to two or more modules, then the tablet is intended to be an FDT tablet. If on the other hand, the tablet is made of more than one module, such as two modules, such additional module is intended to be a “lozenge” module, which provides a longer disintegration time compared to the FDT module according to the invention. The combination of an “FDT” module and a “lozenge” module contributes to another aspect of the invention. A “lozenge” module according to the invention may also comprise elements from the “FDT” modules but is generally different in composition, providing an extended disintegration time. The term “lozenge” is intended to cover that a “lozenge composition” has been “compressed” into a “lozenge module”. In the present context, a “lozenge module” or similar wording is intended to mean that the module during use in the oral cavity is intended to be sucked or licked on. The term “lozenge” is given the ordinary meaning in the art of lozenges. The intention is that the lozenge module may not be chewed. The intention is also that the FDT module may not be chewed. Generally, the “lozenge module” of the present invention may disintegrate upon sucking or licked in minutes, contrary to seconds for orally disintegrating tablets (ODT) or fast disintegrating tablets (FDT) tablets. Hence, the intention is that the “lozenge module” is to deliver cannabidiol over a longer period of time than the FDT module, if the tablet is made as a combination of the two modules. The term “module” is generally intended to be composed of a composition of matter with substantially the same characteristics throughout the module. Hence, if two module are present, then the two modules are different in composition and generally have two different characteristics throughout each module. In the present context, if only one module is present, then this module is considered an FDT tablet. On the other hand, if two modules are present, then the tablet is composed of an FDT tablet or FDT tablet module fused with a lozenge tablet or lozenge module. The term “fused” is intended to mean that the tablet is gathered together by means of compression force. Usually, if two modules are present, the lozenge module is made as the first module and the FDT module is made as the second module. The tablet may be composed of more than two module. The lozenge module may in certain embodiments be replaced by a gum base module. In the present context, the invention provides an attractive bi-phasic delivery of masking, even if the delivery of nicotine is “single-phased”. By the terms “ water-insoluble gum base” or “gum base” or “gum base matrix” or similar wording is meant the mainly water-insoluble ingredients and hydrophobic gum base ingredients. The “gum base” may contain gum base polymers and plasticizers, waxes, emulsifiers, fats and/or fillers. The term “natural resin”, as used herein, means resinous compounds being either polyterpene derived from terpenes of natural origin or resinous compounds derived from gum rosin, wood rosin or tall-oil rosin. Elastomers provide the rubbery, elastomeric and bouncing nature to the gum, which varies depending on this ingredient's chemical structure and how it may be compounded with other ingredients. Elastomers suitable for use in the gum base and gum of the present invention may include natural or synthetic types. Polyvinyl acetate elastomer plasticizers are not considered elastomers according to the invention. Elastomers may be selected from the group consisting of styrene-butadiene copolymers, polyisobutylene, isobutylene-isoprene copolymers, polyethylene, polyurethane or any combination thereof. Preferred elastomers are styrene-butadiene copolymers (SBR), polyisobutylene and isobutylene-isoprene copolymers (BR). Styrene-butadiene type elastomers, or SBR as they may be called, typically are copolymers of from about 20:80 to 60:40 styrenes:butadiene monomers. The ratio of these monomers affects the elasticity of the SBR as evaluated by mooney viscosity. As the styrene:butadiene ratio decreases, the mooney viscosity decreases. The structure of SBR typically consists of straight chain 1,3-butadiene copolymerized with phenylethylene (styrene). The average molecular weight of SBR is <600,000 g/mole. Isobutylene-isoprene type elastomers, or butyl as they may be called, have molar percent levels of isoprene ranging from 0.2 to 4.0. Similar to SBR, as the isoprene:isobutylene ratio decreases, so does the elasticity, measured by mooney viscosity. The structure of butyl rubber typically consists of branched 2-methyl-1,3-butadiene (isoprene) copolymerized with branched 2-methylpropene (isobutylene). The average molecular weight of BR is in the range from 150,000 g/mole to 1,000,000 g/mole. Polyisobutylene, or PIB as they may be called, type elastomers are polymers of 2- methylpropene. The low molecular weight elastomers provide soft chew characteristics to the gum base and still provide the elastic qualities as do the other elastomers. Average molecular weights may range from about 30,000 to 120,000 g/mole and the penetration may range from about 4 millimeters to 20 millimeters. The higher the penetration, the softer the PIB. Similar to the SBR and butyl, the high molecular weight elastomers provide elasticity to the gum. Average molecular weight may range from 120,000 to 1,000,000 g/mole. Polybutene range in average molecular weight from about 5.000 g/mole to about 30.000 g/mole. Useful natural elastomers include natural rubber such as smoked or liquid latex and guayule, natural gums such as jelutong, lechi caspi, perillo, sorva, massaranduba balata, massaranduba chocolate, nispero, rosidinha, chicle, gutta percha, gutta kataiu, niger gutta, tunu, chilte, chiquibul, gutta hang kang. Natural elastomers may also be applied in aspects of the present invention. Elastomer plasticizers vary the firmness of the gum base. Their specificity on elastomer inter-molecular chain breaking (plasticizing) along with their varying softening points cause varying degrees of finished gum firmness and compatibility when used in base. Polyvinyl acetate elastomers plasticizers are examples of elastomer plasticizers of the present invention. Natural resins may be selected from ester gums including as examples glycerol esters of partially hydrogenated rosins, glycerol esters of polymerized rosins, glycerol es- ters of partially dimerized rosins, glycerol esters of tally oil rosins, pentaerythritol esters of partially hydrogenated rosins, methyl esters of rosins, partially hydrogenated methyl esters of rosins, pentaerythritol esters of rosins, synthetic resins such as terpene resins derived from alpha-pinene, beta-pinene, and/or d-limonene, and natural terpene resins. In an embodiment of the invention, the solid dosage form comprises further ingredients selected from the group consisting of flavors, dry-binders, tableting aids, anti-caking agents, emulsifiers, antioxidants, enhancers, mucoadhesives, absorption enhancers, high intensity sweeteners, softeners, colors, active ingredients, water- soluble indigestible polysaccharides, water-insoluble polysaccharides or any combination thereof. The solid dosage form according to the invention is manufactured by applying pressure to a content of particles by suitable compression means. The particles or powder is then pressed into a compact coherent tablet. The particles may for example comprise so-called primary particles or aggregated primary particles. When these are pressed, bonds are established between the particles or granules, thereby conferring a certain mechanical strength to the pressed tablet. It should be noted that the above-introduced terms: powder, primary particles and aggregated primary particles may be somewhat misleading in the sense that the difference between primary particles and aggregated primary particles may very often be looked upon differently depending on the background of the user. Some may for instance regard a sweetener, such as sorbitol, as a primary particle in spite of the fact that sorbitol due to the typically preprocessing performed on sorbitol when delivered to the customer should rather be regarded as some sort of aggregated primary particles. The definition adopted in the description of this invention is that aggregated primary particles refer to macro-particles comprising more or less preprocessed primary particles. When pressure is applied to the particles, the bulk volume is reduced, and the amount of air is decreased. During this process energy is consumed. As the particles come into closer proximity to each other during the volume reduction process, bonds may be established between the particles or granules. The formation of bonds is associated with a reduction in the energy of the system as energy is released. Volume reduction takes place by various mechanisms and different types of bonds may be established between the particles or granules depending on the pressure applied and the properties of the particles or granules. The first thing that happens when a powder is pressed is that the particles are rearranged under low compaction pressures to form a closer packing structure. Particles with a regular shape appear to undergo rearrangement more easily than those of irregular shape. As the pressure increases, further rearrangement is prevented, and subsequent volume reduction is obtained by plastic and elastic deformation and/or fragmentation of the tablet particles. Brittle particles are likely to undergo fragmentation, i.e., breakage of the original particles into smaller units. Plastic deformation is an irreversible process resulting in a permanent change of particle shape, whereas the particles resume their original shape after elastic deformation. Evidently, both plastic and elastic deformation may occur, when compressing a solid dosage form. Several studies of the bond types in pressed tablets have been made over the years, typically in the context of pharmaceuticals and several techniques of obtaining pressed tablets on the basis of available powders has been provided. Such studies have been quite focused on what happens when the volume reduction is performed and how the end-product may be optimized for the given purpose. Several refinements with respect to pressed tablets has for instance been made in the addition of for example binders in the tablet raw materials for the purpose of obtaining a sufficient strength to the final pressed tablet while maintaining acceptable properties, e.g. with respect to release. Contrary to tableted chewing gum, conventional chewing gum may be manufactured by sequentially adding the various chewing gum ingredients to a commercially available mixer known in the art where the finished gum base is already present. After the initial ingredients have been thoroughly mixed, the gum mass is discharged from the mixer and shaped into the desired form such as by rolling into sheets and cutting into sticks, extruded into chunks or casting into pellets. Generally, the ingredients of conventional chewing gum may be mixed by first melting the gum base and adding it to the running mixer. Colors, active agents and/or emulsifiers may also be added at this time. A softener such as glycerin may also be added at this time, along with syrup and a portion of the bulking agent/sweetener. Further portions of the bulking agent/sweetener may then be added to the mixer. A flavoring agent is typically added with the final portion of the bulking agent/sweetener. A high- intensity sweetener is preferably added after the final portion of bulking agent and flavor have been added. The entire mixing procedure typically takes from thirty to forty minutes, but longer mixing times may sometimes be required. Those skilled in the art will recognize that many variations of the above described procedure may be followed. In some embodiments of the invention, the solid dosage form does not include conventional chewing gum, i.e., so-called extruded chewing gum. In accordance with the invention, the tableted solid dosage form according to the invention may comprise about 0.1 to about 75% by weight of an outer coating applied onto the solid dosage form centre. Thus, suitable coating types include hard coatings, film coatings and soft coatings of any composition including those currently used in coating of tableted solid dosage form. One presently preferred outer coating type is a hard coating, which term is used in the conventional meaning of that term including sugar coatings and sugar-free (or sugarless) coatings and combinations thereof. The object of hard coating is to obtain a sweet, crunchy layer, which is appreciated by the consumer and it may moreover protect the solid dosage form centres for various reasons. In a typical process of providing the solid dosage form centres with a protective sugar coating, the solid dosage form centres are successively treated in suitable coating equipment with aqueous solutions of crystallisable sugar such as sucrose or dextrose, which, depending on the stage of coating reached, may contain other functional ingredients, e.g. fillers, binding agents, colours, etc. In the present context, the sugar coating may contain further functional or active compounds including flavour compounds and/or active compounds. In a typical hard coating process as it will be described in detail in the following, a suspension containing crystallisable sugar and/or polyol is applied onto the solid dosage form centres and the water it contains is evaporated off by blowing with air. This cycle must be repeated several times, typically 3 to 80 times, in order to reach the swelling required. The term “swelling” refers to the increase in weight or thickness of the products, as considered at the end of the coating operation by comparison with the beginning, and in relation to the final weight or thickness of the coated products. In accordance with the present invention, the coating layer constitutes about 0.1 to about 75% by weight of the finished solid dosage form element, such as about 10 to about 60% by weight, including about 15 to about 50% by weight. In an embodiment of the invention, the product is a pouch. In one aspect of the invention, the particles used for tableting may also be present in a pouch as a powder. Hence, this aspect of the invention includes particles in a pouch without tableting, but as a powder or part of a powder with other powders or powder ingredients. It follows that the directly compressible (DC) and non-directly compressible (non-DC) sugar alcohol particles of the invention may be included in the pouch according to the invention. It is noted that additional ingredients may be present in the pouch, such as water-soluble fibers or water-insoluble fibers, including microcrystalline cellulose. According to an advantageous embodiment of the invention the pouch comprises a water-permeable membrane, such as a woven or non-woven fabric. The pouches according to the invention comprise openings, where the characteristic opening dimension is adapted to a characteristic dimension of the particles so as to retain the matrix composition inside the pouch before use and/or to retain a part of the content inside the pouch during use. In other words, according to the various embodiments, the pouch forms a membrane allowing passage of saliva and prevents or inhibits passage of at least a part of the content. The membrane of the pouch may be of any suitable material e.g. woven or non-woven fabric (e.g. cotton, fleece etc.), heat sealable non-woven cellulose or other polymeric materials such as a synthetic, semi-synthetic or natural polymeric material. An example of suitable pouch material is paper made of pulp and a small amount of wet strength agent. A material suitable for use must provide a semi- permeable membrane layer to prevent the powder or composition from leaving the bag or pouch during use. Suitable materials are also those that do not have a significant impact on the release of the active ingredients from the pouch. The powder is filled into pouches and is maintained in the pouch by a sealing. An ideal pouch is chemically and physically stable, it is pharmaceutically acceptable, it is insoluble in water, it is easy to fill with powder and seal, and it provides a semi- permeable membrane layer which prevent the powder from leaving the bag, but permit saliva and therein dissolved or sufficiently small, suspended components from the powder in the pouch to pass through said pouch. The pouch may be placed in the oral cavity by the user. Saliva then enters into the pouch, and the active ingredient and other components, which are soluble in saliva, start to dissolve and are transported with the saliva out of the pouch into the oral cavity. In some embodiments of the invention, the pouch may be masticated in a similar way as chewing a gum. This is particularly advantageous when the particles comprise gum base. Hence, the pouch may be masticated into a coherent residual containing water-insoluble components. According to embodiments of the invention, flavors may be selected from the group consisting of coconut, coffee, chocolate, vanilla, grape fruit, orange, lime, menthol, liquorice, caramel aroma, honey aroma, peanut, walnut, cashew, hazelnut, almonds, pineapple, strawberry, raspberry, tropical fruits, cherries, cinnamon, peppermint, wintergreen, spearmint, eucalyptus, and mint, fruit essence such as from apple, pear, peach, strawberry, apricot, raspberry, cherry, pineapple, and plum essence. The essential oils include peppermint, spearmint, menthol, eucalyptus, clove oil, bay oil, anise, thyme, cedar leaf oil, nutmeg, and oils of the fruits mentioned above. Antioxidants suitable for use include butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), betacarotenes, tocopherols, acidulants such as Vitamin C (ascorbic acid or corresponding salts (ascorbates)), propyl gallate, catechins, green tea extract other synthetic and natural types or mixtures thereof. High intensity sweetening agents can also be used according to preferred embodiments of the invention. Preferred high intensity sweeteners include, but are not limited to sucralose, aspartame, salts of acesulfame, alitame, neotame, saccharin and its salts, cyclamic acid and its salts, glycyrrhizin, dihydrochalcones, thaumatin, monellin, monk fruit extract, advantame, stevioside and the like, alone or in combination. In order to provide longer lasting sweetness and flavor perception, it may be desirable to encapsulate or otherwise control the release of at least a portion of the high intensity sweeteners. Techniques such as wet granulation, wax granulation, spray drying, spray chilling, fluid bed coating, conservation, encapsulation in yeast cells and fiber extrusion may be used to achieve desired release characteristics. Encapsulation of sweetening agents can also be provided using another formulation component such as a resinous compound. Usage level of the high-intensity sweetener will vary considerably and will depend on factors such as potency of the sweetener, rate of release, desired sweetness of the product, level and type of flavor used and cost considerations. Thus, the active level of artificial sweetener may vary from about 0.001 to about 8% by weight (preferably from about 0.02 to about 8% by weight). When carriers used for encapsulation are included, the usage level of the encapsulated high-intensity sweetener will be proportionately higher. The invention, if desired, may include one or more fillers/texturizers including as examples, magnesium- and calcium carbonate, sodium sulphate, ground limestone, silicate compounds such as magnesium- and aluminum silicate, kaolin and clay, aluminum oxide, silicium oxide, talc, titanium oxide, mono-, di- and tri-calcium phosphates, and combinations thereof. According to an embodiment of the invention, one preferred filler/texturizer is calcium carbonate. "Phytocannabinoids" are cannabinoids that originate in nature and can be found in the cannabis plant. The phytocannabinoids can be present in an extract including a botanical drug substance, isolated, or reproduced synthetically. "Syntho-cannabinoids" are those compounds capable of interacting with the cannabinoid receptors (CB1 and/or CB2) but are not found endogenously or in the cannabis plant. Examples include WIN 55212 and rimonabant. An "isolated phytocannabinoid" or “isolated cannabinoid”, such as “isolated cannabidiol” is one which has been extracted from the cannabis plant and purified to such an extent that the additional components such as secondary and minor cannabinoids and the non-cannabinoid fraction have been substantially removed. A "synthetic cannabinoid" is one which has been produced by chemical synthesis. This term includes modifying an isolated phytocannabinoid, by, for example, forming a pharmaceutically acceptable salt thereof. A "substantially pure" cannabinoid is defined as a cannabinoid, such as cannabidiol, which is present at greater than 95% (w/w) pure. More preferably greater than 96% (w/w) through 97% (w/w) thorough 98% (w/w) to 99% % (w/w) and greater. A "highly purified" cannabinoid, such as cannabidiol, is defined as a cannabinoid that has been extracted from the cannabis plant and purified to the extent that other cannabinoids and non-cannabinoid components that are co-extracted with the cannabinoids have been substantially removed, such that the highly purified cannabinoid is greater than or equal to 95% (w/w) pure. “Plant material” is defined as a plant or plant part (e.g. bark, wood, leaves, stems, roots, flowers, fruits, seeds, berries or parts thereof) as well as exudates, and includes material falling within the definition of “botanical raw material” in the Guidance for Industry Botanical Drug Products Draft Guidance, August 2000, US Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research. The term “Cannabis plant(s)” encompasses wild type Cannabis sativa and also variants thereof, including cannabis chemovars which naturally contain different amounts of the individual cannabinoids, Cannabis sativa subspecies indica including the variants var. indica and var. kafiristanica, Cannabis indica, Cannabis ruderalis and also plants which are the result of genetic crosses, self-crosses or hybrids thereof. The term “Cannabis plant material” is to be interpreted accordingly as encompassing plant material derived from one or more cannabis plants. For the avoidance of doubt it is hereby stated that “cannabis plant material” includes dried cannabis biomass. Cannabinoids can be split into different groups as follows: Phytocannabinoids; Endocannabinoids; and Synthetic cannabinoids. Cannabinoid receptors can be activated by three major groups of agonist ligands, for the purposes of the present invention and whether or not explicitly denominated as such herein, lipophilic in nature and classed respectively as: endocannabinoids (produced endogenously by mammalian cells); phytocannabinoids (such as cannabidiol, produced by the cannabis plant); and synthetic cannabinoids (such as HU-210). The following non-limiting examples illustrate different variations of the present invention. The examples are meant for indicating the inventive concept; hence the mentioned examples should not be understood as exhaustive for the present. EXAMPLES Example 1 Pre-clinical CBD-cholinergic induced salivation studies A proof of concept pilot study was made to confirm xerostomia rodent model validity. Furthermore, the purpose of this study was to establish the dose range to induce xerostomia and the time estimation of xerostomia induction in rodents from overactive bladder (OAB) anticholinergic (AC) and tricyclic antidepressant (TCA). A positive control study with concomitant THC and CBD administration to confirm effects was also performed in this proof of concept pilot study prior to a CBD treatment study. Pilot study designs are illustrated in Fig. 1. Collectively, baseline salivation measurements were performed 3 times during 1 week for all animals prior to both studies. Salivation was measured as described by Andreis, K. et al. 2022, using a phenol red-coated thread which is inserted into a fire-polished glass capillary with 3 mm extending outside the opening and placed under the tongue of an isoflurane anesthetized rat for 10 s. The discoloration in mm is taken as a measure of basal salivation. For the positive control study, 4.4 mg/kg THC and 4.4 mg/kg CBD, which each equals a 70 kg human dose of 50 mg/kg was administered perorally employing a lozenge composition provided in minicapsules for oral gavage. CBD effects on salivation was measured at the expected Cmax (ie. maximum concentration), which is approximately 2 hrs. post administration using the capillary method described above. The pilot study aimed to establish AC, e.g. by using Oxybutynin and TCA, e.g. by using Amitriptyline, administration duration period for inducing xerostomia prior to CBD treatment initiation. Table 1 shows conditions often treated with anticholinergics, and Table 2 shows commonly prescribed anticholinergic drug categories and drugs associated with dry mouth. Clinical conditions often treated with anticholinergic medications Psychiatric conditions Schizophrenia, schizoaffective disorder Bipolar disorder Depression Obsessive-compulsive disorder Anxiety Insomnia Neurologic conditions Parkinson disease Epilepsy Somatic problems Urinary incontinence Gastroesophageal reflux, peptic ulcer disease Cardiovascular diseases Muscle spasm Low back pain Neuropathic pain Irritable bowel syndrome Obstructive pulmonary disease Allergy Table 1: Clinical conditions often treated with anticholinergic drugs. From Arany et al, 2022. Medication (frequency of Xerostomia risk Muscarinic receptor usage) antagonism (Ki)* Selective serotonin reuptake inhibitors (22%)

Paroxetine 1.98 72.0 Escitalopram 2.19 1240.0 Sertraline 1.48 1300.0 Fluoxetine 1.64 2000.0 Citalopram 2.01 2200.0 Serotonin-norepinephrine reuptake inhibitors (11%)

Antipsychotics Olanzapine 13.0 Chlorpromazine 4.00 67.0 Quetiapine 2.42 1320.0 Risperidone >10,000.0 Overactive bladder medications (30%)

Trospium 0.8 Darifenacin 7.41 0.8 Tolterodine 4.82 3.4

Table 2: Commonly prescribed anticholinergic drug categories and drugs associated with dry mouth. From Arany et al, 2022. The AC/TCA drugs were administered i.v., through the tail vein daily as prescribed. Effects on salivation were evaluated 3 times weekly to estimate the time to induce stabile xerostomia levels for the treatment study. The pharmacokinetic profile of chosen AC and TCA drugs was evaluated to establish the protocol for saliva measurement post administration. However, salivation was measured approximately at 9:00 A.M post administration to avoid disturbances of the circadian rhythm. Example 2 CBD treatment study CBD treatment study was initiated by establishing baseline salivation for 1 week like it was done in the proof of concept study. Hereafter, the rodents was split into 9 groups as depicted in figure 2. Xerostomia was induced by AC and TCA respectively- as established in the proof of concept study, followed by treatment with 3 different dosages of CBD; 4.4 mg/kg (50 mg/kg human dosage), 8.8 mg/kg (100 mg/kg human dosage) and 17.6 mg/kg (200 mg/kg human dosage). The CBD was provided in a lozenge composition by oral gavage. The effect of CBD on xerostomia was measured 2 hrs post administration for 2 weeks. During this treatment regimen, a positive control group (4 mg/kg THC + 4 mg/kg CBD) and Vehicle control group (lozenge composition made according to embodiments of the invention) was included together with negative control groups receiving 4.4 mg/kg CBD (50 mg/kg human dosage), 8.8 mg/kg CBD (100 mg/kg human dosage) and 17.6 mg/kg CBD (200 mg/kg human dosage), respectively. Surprisingly good results were seen in terms of the effect on xerostomia. Example 3 CBD treatment study A 50 day CBD treatment study of xerostomia in rodents was conducted, with xerostomia induced by oxybutynin administration. The therapeutical potential of CBD for alleviation of xerostomia was tested, examining the effectiveness across a range of doses. In the study design as outlined in figure 3, rodents were split into 9 groups, and salivation was tested as follows. A single dose of CBD was applied daily on days 1- 50 with days 1-7 having the function of pretreatment. Then, starting at day 8 and throughout the remainder of the study, attenuation of salivation was induced by administration of a daily, single dose of oxybutynin. The daily dose of oxybutynin was administered 1.5 hours after administration of CBD. In one group (a positive control group), pilocarpine, which is known to induce salivation, was administered intravenously on days 8, 29, and 50, corresponding to the days of saliva collection. Saliva collection was made on days 8, 29, and 50, two hours after administration of CBD, corresponding to 30 minutes after administration of oxybutynin. 3 different dosages of CBD were applied: 4.4 mg/kg (50 mg/kg human dosage), 8.8 mg/kg (100 mg/kg human dosage) and 17.6 mg/kg (200 mg/kg human dosage). The dosage of oxybutynin applied in all relevant groups was 27 mg/kg. As seen in figure 3, the following groups (n=10/group) were included in the study. One group exposed to the delivery vehicle only (vehicle control), 3 groups exposed to various dosages of CBD only (CBD dosage response), one group exposed to oxybutynin only (xerostomia induction control), 3 groups exposed to Oxybutynin and various dosages of CBD (treatment regimens), and one group exposed to oxybutynin and pilocarpine (standard treatment for reversal of xerostomia). A decrease in salivation was observed, along with heightened ductal hyperplasia and fibrosis in the positive control group exposed to oxybutynin only. Conversely, in the groups tested with both oxybutynin and CBD, a dose-dependent mitigation of the symptoms was seen.

Claims

CLAIMS 1. Cannabidiol for use in the alleviation or treatment of xerostomia in patients in need thereof.

2. Cannabidiol for use in the alleviation or treatment of xerostomia according to claim 1, wherein the cannabidiol is administered orally, such as peroral administration or by sublingual administration.

3. Cannabidiol for use in the alleviation or treatment of xerostomia according to claims 1-2, wherein the cannabidiol is administered in a unit dose of 10 to 500 mg cannabidiol.

4. Cannabidiol for use in the alleviation or treatment of xerostomia according to any of the preceding claims, wherein the cannabidiol is administered in a unit dose of 20 to 400 mg cannabidiol.

5. Cannabidiol for use in the alleviation or treatment of xerostomia according to any of the preceding claims, wherein the cannabidiol is administered in a unit dose of 50 to 200 mg cannabidiol.

6. Cannabidiol for use in the alleviation or treatment of xerostomia according to any of the preceding claims, wherein the cannabidiol is administered in one dose per day.

7. Cannabidiol for use in the alleviation or treatment of xerostomia according to any of the preceding claims, wherein the cannabidiol is administered in two doses per day.

8. Cannabidiol for use in the alleviation or treatment of xerostomia according to any of the preceding claims, wherein the cannabidiol is administered in three or four doses per day.

9. Cannabidiol for use in the alleviation or treatment of xerostomia according to any of the preceding claims, wherein the cannabidiol is administered in a dosing interval of 4 to 8 hours, such as about 6 hours.

10. Cannabidiol for use in the alleviation or treatment of xerostomia according to any of the preceding claims, wherein the cannabidiol is administered in a dosing interval of 10 to 14 hours, such as about 12 hours.

11. Cannabidiol for use in the alleviation or treatment of xerostomia according to any of the preceding claims, wherein the cannabidiol is administered in a dosing interval of 16 to 20 hours, such as about 18 hours.

12. Cannabidiol for use in the alleviation or treatment of xerostomia according to any of the preceding claims, wherein the cannabidiol is administered in a dosing interval of 22 to 26 hours, such as about 24 hours.

13. Cannabidiol for use in the alleviation or treatment of xerostomia according to any of the preceding claims, wherein the cannabidiol is administered for a period of at least 7 days, such as at least 14 days, such as at least 21 days, such as at least 30 days.

14. Cannabidiol for use in the alleviation or treatment of xerostomia according to any of the preceding claims, wherein the cannabidiol is administered on a permanent basis.

15. Cannabidiol for use in the alleviation or treatment of xerostomia according to any of the preceding claims, wherein the cannabidiol induces saliva secretion.

16. Cannabidiol for use in the alleviation or treatment of xerostomia according to any of the preceding claims, wherein saliva secretion is increased by at least 10% in the alleviation or treatment of xerostomia, such as at least 20%, such as at least 30%, such as at least 50%.

17. Cannabidiol for use in the alleviation or treatment of xerostomia according to any of the preceding claims, wherein xerostomia is associated with salivary gland hypofunction.

18. Cannabidiol for use in the alleviation or treatment of xerostomia according to any of the preceding claims, wherein the alleviation or treatment of xerostomia involves stimulation of acetylcholine receptors (mAChRs) on salivary secretory cells.

19. Cannabidiol for use in the alleviation or treatment of xerostomia according to any of the preceding claims, wherein the cannabidiol acts as a CB1 receptor antagonist.

20. Cannabidiol for use in the alleviation or treatment of xerostomia according to any of the preceding claims, wherein the cannabidiol is administered in a dosage regimen comprising a drug that causes xerostomia.

21. Cannabidiol for use in the alleviation or treatment of xerostomia according to any of the preceding claims, wherein the cannabidiol is administered together with a drug that causes xerostomia.

22. Cannabidiol for use in the alleviation or treatment of xerostomia according to any of the preceding claims, wherein the cannabidiol is administered to counteract a drug that causes xerostomia.

23. Cannabidiol for use in the alleviation or treatment of xerostomia according to any of the preceding claims, wherein the cannabidiol is the active ingredient alleviating or treating xerostomia.

24. Cannabidiol for use in the alleviation or treatment of xerostomia according to any of the preceding claims, wherein the cannabidiol is the active ingredient alleviating or treating xerostomia without other active ingredients having the same effect or function.

25. Cannabidiol for use in the alleviation or treatment of xerostomia according to any of the preceding claims, wherein the cannabidiol is not administered with other active ingredients that do not cause xerostomia, such as analgesics that does not cause xerostomia.

26. Cannabidiol for use in the alleviation or treatment of xerostomia according to any of the preceding claims, wherein the cannabidiol is administered to counteract a drug that causes xerostomia selected from the group consisting of anticholinergic drugs, sympathomimetic drugs, benzodiazepines, anti-migraine agents, and combinations thereof.

27. Cannabidiol for use in the alleviation or treatment of xerostomia according to any of the preceding claims, wherein the cannabidiol is administered as the only cannabinoid for alleviating or treating xerostomia.

28. Cannabidiol for use in the alleviation or treatment of xerostomia according to any of the preceding claims, wherein the cannabidiol is administered as the only major cannabinoid.

29. Cannabidiol for use in the alleviation or treatment of xerostomia according to any of the preceding claims, wherein the cannabidiol is administered without a major amount of other cannabinoids, such as THC.

30. Cannabidiol for use in the alleviation or treatment of xerostomia according to any of the preceding claims, wherein the cannabidiol is a CB1 receptor antagonist

31. Cannabidiol for use in the alleviation or treatment of xerostomia according to any of the preceding claims, wherein the cannabidiol is a CB1 receptor antagonist that prevents reduction of acetylcholine release by a drug that causes xerostomia.

32. Cannabidiol for use in the alleviation or treatment of xerostomia according to any of the preceding claims, wherein the cannabidiol is further applied for alleviating or treating inflammatory conditions in the oral cavity.

33. Cannabidiol for use in the alleviation or treatment of xerostomia according to any of the preceding claims, wherein the cannabidiol is further applied as an anti-microbial treatment.

34. Cannabidiol for use in the alleviation or treatment of xerostomia according to any of the preceding claims, wherein the cannabidiol is further applied to treat caries.

35. Cannabidiol for use in the alleviation or treatment of xerostomia according to any of the preceding claims, wherein the cannabidiol is further administered with oral care agents.

36. Cannabidiol for use in the alleviation or treatment of xerostomia according to any of the preceding claims, wherein the cannabidiol is present in a purity of at least 90% (w/w), such as at least 95% (w/w), such as at least 98% (w/w).

37. Cannabidiol for use in the alleviation or treatment of xerostomia according to any of the preceding claims, wherein the cannabidiol is an isolated cannabidiol.

38. Cannabidiol for use in the alleviation or treatment of xerostomia according to any of the preceding claims, wherein the cannabidiol does not include cannabidiol extract or cannabidiol distillates.

39. Cannabidiol for use in the alleviation or treatment of xerostomia according to any of the preceding claims, wherein the cannabidiol does not include cannabidiol in a purity of less than 90% (w/w).

40. Solid dosage form comprising cannabidiol for use in the alleviation or treatment of xerostomia according to any of the preceding claims.

41. Solid dosage form comprising cannabidiol for use in the alleviation or treatment of xerostomia according to claim 40, wherein the solid dosage form comprises cannabidiol in an amount of at least 5% by weight of the solid dosage form, such as at least 10% by weight of the solid dosage form, such as at least 20% by weight of the solid dosage form, such as at least at least 30% by weight of the solid dosage form.

42. Solid dosage form comprising cannabidiol for use in the alleviation or treatment of xerostomia according to claims 40-41, wherein the solid dosage form comprises triglycerides in an amount of 1.0 to 10.0% by weight of the solid dosage form, such as 2.0 to 5.0% by weight of the solid dosage form.

43. Solid dosage form comprising cannabidiol for use in the alleviation or treatment of xerostomia according to claims 40-42, wherein the solid dosage form comprises bulk sweeteners in an amount of 20 to 90% by weight of the solid dosage form, such as 30 to 70% by weight of the solid dosage form.

44. Solid dosage form comprising cannabidiol for use in the alleviation or treatment of xerostomia according to claims 40-43, wherein the solid dosage form comprises sugar alcohols selected from the group consisting of sorbitol, xylitol, maltitol, isomalt, mannitol, erythritol, lactitol, and combinations thereof.

45. Solid dosage form comprising cannabidiol for use in the alleviation or treatment of xerostomia according to claims 40-44, wherein the solid dosage form comprises one or more saccharides.

46. Solid dosage form comprising cannabidiol for use in the alleviation or treatment of xerostomia according to claims 40-45, wherein the solid dosage form comprises further ingredients selected from the group consisting of flavors, dry-binders, tableting aids, anti-caking agents, surfactants, emulsifiers, antioxidants, enhancers, mucoadhesives, absorption enhancers, high intensity sweeteners, softeners, colors, further active ingredients, water-soluble indigestible polysaccharides, water-insoluble polysaccharides, and combinations thereof.

47. Solid dosage form comprising cannabidiol for use in the alleviation or treatment of xerostomia according to claims 40-46, wherein the solid dosage form comprises one or more insoluble components selected from the group consisting of silica, microcrystalline cellulose, cellulose, silicified microcrystalline cellulose, clay, talc, starch, pregelatinized starch, calcium carbonate, dicalcium phosphate, magnesium carbonate, magnesium-alumino-metasilicates, hyper porous silica, and mixtures thereof.

48. Tablet comprising cannabidiol for use in the alleviation or treatment of xerostomia as defined in any one of claims 40-47, wherein the tablet comprises directly compressible (DC) sugar alcohol particles and non-directly compressible (non-DC) sugar alcohol particles.

49. Tablet comprising cannabidiol for use in the alleviation or treatment of xerostomia according to claim 48, wherein the tablet comprises directly compressible (DC) sugar alcohol particles and non-directly compressible (non-DC) sugar alcohol particles in a ratio between 0.2 and 1.2, such as a ratio between 0.3 and 0.7.

50. Tablet comprising cannabidiol for use in the alleviation or treatment of xerostomia according to claims 48-49, wherein the tablet comprises one or more binders in an amount of 0.1 to 6% by weight of the tablet.

51. Tablet comprising cannabidiol for use in the alleviation or treatment of xerostomia according to claims 48-50, wherein the tablet comprises at least two modules.

52. Tablet comprising cannabidiol for use in the alleviation or treatment of xerostomia according to claims 48-51, wherein the tablet comprises at least two modules, and wherein the tablet comprises directly compressible (DC) sugar alcohol particles and non-directly compressible (non-DC) sugar alcohol particles located in the same module.

53. Tablet comprising cannabidiol for use in the alleviation or treatment of xerostomia according to claims 48-52, wherein the tablet comprises directly compressible (DC) sugar alcohol particles and non-directly compressible (non-DC) sugar alcohol particles, and wherein the non-directly (non-DC) sugar alcohol particles are selected from the group consisting of non-directly (non-DC) sugar alcohol particles of xylitol, maltitol, isomalt, mannitol, erythritol, lactitol, and combinations thereof.

54. Tablet comprising cannabidiol for use in the alleviation or treatment of xerostomia according to claims 48-53, wherein the tablet comprises directly compressible (DC) sugar alcohol particles and non-directly compressible (non-DC) sugar alcohol particles, and wherein the directly (DC) sugar alcohol particles are selected from the group consisting of directly (DC) sugar alcohol particles of sorbitol, xylitol, maltitol, isomalt, mannitol, erythritol, lactitol, and combinations thereof.

55. Tablet comprising cannabidiol for use in the alleviation or treatment of xerostomia according to claims 48-54, wherein the tablet is a chewable tablet.

56. Chewing gum comprising cannabidiol for use in a method for the alleviation or treatment of xerostomia as defined in any one of claims 40-47, wherein the chewing gum comprises gum base in an amount of 20-40% by weight of the chewing gum, and wherein the chewing gum is designed to be masticated into a coherent residual containing water-insoluble components.

57. Chewing gum comprising cannabidiol for use in a method for the alleviation or treatment of xerostomia according to claim 56, wherein the chewing gum comprises gum base, and wherein the gum base comprises an elastomer selected from the group consisting of styrene-butadiene rubber (SBR), butyl rubber, polyisobutylene (PIB), and combinations thereof.

58. Chewing gum comprising cannabidiol for use in a method for the alleviation or treatment of xerostomia according to claims 56-57, wherein the chewing gum comprises gum base, and wherein the gum base comprises at least 5% by weight of elastomer.

59. Chewing gum comprising cannabidiol for use in a method for the alleviation or treatment of xerostomia according to claims 56-58, wherein the chewing gum comprises gum base, and wherein the gum base comprises gum base resins selected from natural resins and/or synthetic resins.

60. Chewing gum comprising cannabidiol for use in a method for the alleviation or treatment of xerostomia according to claims 56-59, wherein the chewing gum comprises gum base, and wherein the gum base comprises at least 5% by weight of gum base resins.

61. Chewing gum comprising cannabidiol for use in a method for the alleviation or treatment of xerostomia according to claims 56-60, wherein the chewing gum comprises at least two compressed modules.

62. Chewing gum comprising cannabidiol for use in a method for the alleviation or treatment of xerostomia according to claims 56-61, wherein the chewing gum comprises at least two compressed modules, and wherein the two modules are different in composition.

63. Chewing gum comprising cannabidiol for use in a method for the alleviation or treatment of xerostomia according to claims 56-62, wherein the chewing gum comprises at least two compressed modules, and wherein at least one of the two compressed modules does not comprise gum base.

64. Lozenge comprising cannabidiol for use in a method for the alleviation or treatment of xerostomia as defined in any one of claims 40-47, wherein the lozenge comprises one or more disintegrants operable to disintegrate the lozenge within a period of 3 minutes or less in contact with oral saliva.

65. Lozenge comprising cannabidiol for use in a method for the alleviation or treatment of xerostomia according to claim 64, wherein the lozenge comprises one or more disintegrants operable to disintegrate the lozenge within a period of 1 minute or less in contact with oral saliva.

66. Lozenge comprising cannabidiol for use in a method for the alleviation or treatment of xerostomia according to claims 64-65, wherein the lozenge comprises one or more disintegrants selected from the group consisting of sodium croscarmellose, crospovidone, sodium starch glycolate, and combinations thereof.

67. Lozenge comprising cannabidiol for use in a method for the alleviation or treatment of xerostomia according to claims 64-66, wherein the lozenge comprises one or more disintegrants in an amount of 0.5 to 25% by weight of the lozenge.

68. Pouch comprising cannabidiol for use in a method for the alleviation or treatment of xerostomia as defined in any one of claims 40-47, wherein the pouch comprises one or more insoluble components selected from the group consisting of silica, clay, talc, starch, pregelatinized starch, calcium carbonate, dicalcium phosphate, magnesium carbonate, magnesium-alumino-metasilicates, hyper porous silica and mixtures thereof.

69. Pouch comprising cannabidiol for use in a method for the alleviation or treatment of xerostomia according to claim 68, wherein the pouch comprises one or more insoluble fibres.

70. Pouch comprising cannabidiol for use in a method for the alleviation or treatment of xerostomia according to claims 68-69, wherein the pouch comprises one or more insoluble fibres selected from wheat fibers, pea fibers, rice fiber, maize fibers, oat fibers, tomato fibers, barley fibers, rye fibers, sugar beet fibers, buckwheat fibers, potato fibers, cellulose fibers, apple fibers, cocoa fibers, cellulose fibers, bran fibers, bamboo fibers, powdered cellulose, microcrystalline cellulose, and combinations thereof.

71. Method of treating or alleviating xerostomia in patients in need thereof by administering an effective amount of cannabidiol.

72. Method according to claim 71, wherein the method includes cannabidiol as defined in any one of claims 2-70.